Research programme: Mucosal associated invariant T cell therapies - Pluri
Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Pluri
- Developer Bar-Ilan Research & Development Company; Pluri
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours